Phase I multiple-dose trial in male volunteers.

Trial Profile

Phase I multiple-dose trial in male volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2010

At a glance

  • Drugs SUVN 502 (Primary)
  • Indications Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease; Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Suven Life Sciences
  • Most Recent Events

    • 14 Oct 2009 According to a Suven Life Sciences media release, SUVN 502 has shown to be safe at all doses tested with excellent bioavailability and a half life suitable for once-daily treatment.
    • 12 Jul 2009 Results have been presented at ICAD 2009.
    • 17 Apr 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top